Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
2.200
-0.040 (-1.79%)
Jun 5, 2025, 9:53 AM - Market open
Skye Bioscience Stock Forecast
SKYE's stock price has decreased by -81.27% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Skye Bioscience stock ranges from a low of $14 to a high of $20. The average analyst price target of $16.6 forecasts a 654.55% increase in the stock price over the next year.
Price Target: $16.60 (+654.55%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for Skye Bioscience stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 5 | 5 | 6 | 6 | 6 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +536.36% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $15 | Buy | Reiterates | $15 | +581.82% | Mar 21, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 28, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $20 | Buy | Initiates | $20 | +809.09% | Sep 30, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $20 | Buy | Reiterates | $20 | +809.09% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
n/a
from 3.67M
Revenue Next Year
n/a
EPS This Year
-1.22
from -0.73
EPS Next Year
-1.42
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.05 | -1.12 | -1.47 | ||
| Avg | -1.22 | -1.42 | -1.94 | ||
| Low | -1.34 | -1.77 | -2.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.